From: Palliative radiotherapy for painful lymph node metastases
Characteristic | No | % |
---|---|---|
Age, years | ||
Median | 66 | |
Range | 36–84 | |
Sex | ||
Female | 13 | 52 |
Male | 12 | 48 |
ECOG performance status | ||
0 | 4 | 16 |
1 | 10 | 40 |
2 | 7 | 28 |
3 | 4 | 16 |
4 | 0 | 0 |
Interval from first tumor diagnosis to radiotherapy, months | ||
Median | 15 | |
Range | 0–239 | |
Primary site of the tumors | ||
Lung | 5 | 20 |
Gastrointestinal system | 6 | 24 |
Gynecological system | 6 | 24 |
Head and neck | 2 | 8 |
Urogenital system | 2 | 8 |
Breast | 2 | 8 |
Other | 2 | 8 |
Location of the lymph node metastases (n = 30) | ||
Neck | 4 | 13 |
Supraclavicular region | 5 | 17 |
Axilla | 2 | 7 |
Chest | 4 | 13 |
Abdomen | 5 | 17 |
Pelvis | 8 | 27 |
Inguinal region | 2 | 7 |
Worst pain score at baseline | ||
0–2 | 0 | 0 |
3–4 | 4 | 16 |
5–7 | 10 | 40 |
8–10 | 11 | 44 |
Neuropathic component of index pain | ||
No | 17 | 68 |
Yes | 8 | 32 |
Non-index pain of malignant or unknown origin at baseline | ||
No | 23 | 92 |
Yes | 2 | 8 |
Opioid analgesic use at baseline | ||
No | 9 | 36 |
Yes | 16 | 64 |
Total radiation dose, Gy | ||
Median | 30 | |
Range | 8–60 | |
≤ 10 | 2 | 8 |
10–20 | 2 | 8 |
20–30 | 10 | 40 |
30–40 | 6 | 24 |
> 40 | 5 | 20 |
Concurrent systemic therapy | ||
Chemotherapy | 8 | 32 |
Targeted or immune-based therapy | 3 | 12 |
None | 14 | 56 |